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Abstract
Background: Hyperthyroidism is accompanied by osteoporosis with higher incidence of fracture rates. The present
work aimed to study bone status in hyperthyroidism and to elucidate the impact of severity, duration, and etiology
of hyperthyroidism on biochemical markers of bone turnover and bone mineral density (BMD).
Methods: Fifty-two male patients with hyperthyroidism, 31 with Graves’ disease (GD) and 21 with toxic
multinodular goiter (TNG), with an age ranging from 23 to 65 years were included, together with 25 healthy
euthyroid men with matched age as a control group. In addition to full clinical examination, patients and controls
were subjected to measurement of BMD using dual-energy X-ray absorptiometery scanning of the lower half of
the left radius. Also, some biochemical markers of bone turnover were done for all patients and controls.
Results: Biochemical markers of bone turnover: included serum bone specific alkaline phosphatase, osteocalcin,
carboxy terminal telopeptide of type l collagen also, urinary deoxypyridinoline cross-links (DXP), urinary DXP/urinary
creatinine ratio and urinary calcium/urinary creatinine ratio were significantly higher in patients with GD and TNG
compared to controls (P < 0.01). However, there was non-significant difference in these parameters between GD
and TNG patients (P > 0.05). BMD was significantly lower in GD and TNG compared to controls, but the Z-score of
BMD at the lower half of the left radius in patients with GD (-1.7 ± 0.5 SD) was not significantly different from
those with TNG (-1.6 ± 0.6 SD) (>0.05). There was significant positive correlation between free T3 and free T4 with
biochemical markers of bone turnover, but negative correlation between TSH and those biochemical markers of
bone turnover. The duration of the thyrotoxic state positively correlated with the assessed bone turnover markers,
but it is negatively correlated with the Z-score of BMD in the studied hyperthyroid patients (r = -0.68, P < 0.0001).
Conclusion: Men with hyperthyroidism have significant bone loss with higher biochemical markers of bone
turnover. The severity and the duration of the thyrotoxic state are directly related to the derangement of
biochemical markers of bone turnover and bone loss.
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Background
Thyroid hormones are necessary for normal skeletal
growth, maturation, basic metabolism, and bone turn-
over [1]. Hyperthyroidism is accompanied by osteoporo-
sis or osteopenia with increased rates of bone formation
and bone resorption with predominance of resorption
[2,3]. And higher incidence of fracture rates [4].
Bone densitometric studies revealed that bone mineral
density (BMD) is decreased in all skeletal sites, including
spine, femur, radius, and total body in patients with
hyperthyroidism [5]. However, the deleterious effect of
excess thyroid hormone on bone is reported to be more
accentuated in areas consisting mainly of cortical bone
like femoral neck and forearm [3,6]. On the other hand,
Jodar et al (1997) reported that, there is also, a general-
ized reduction of BMD in the axial skeleton [7].
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hyperthyroidism is recommended in cortical bones than
trabecular bones [8].
Biochemical markers that reflect remodeling or turn-
over of bone can be measured in urine or blood includ-
ing resorption markers and formation markers [9].
Resorption markers include tartrate resistant acid phos-
phatase, and products of bone breakdown as calcium
and bone matrix degradation products like hydroxypro-
line, pyridinium cross-links, and telopeptides [10]. Bone
formation markers include alkaline phosphatase enzyme,
and three products of bone matrix synthesis which are
osteocalcin, amino-and carboxy-terminal procollagen l
extension peptide [11,12].
It is reported that bone resorption markers, as urinary
pyridinoline and deoxypyridinoline are increased 7-8
times in hyperthyroidism more than age and sex
matched controls [13]. On the other hand, serum osteo-
calcin and bone-specific alkaline phosphatase, reflecting
bone formation, were increased to a less degree com-
pared to the increase of urinary pyridinoline cross-links,
suggesting the imbalance between bone formation and
resorption with subsequent bone loss in hyperthyroid-
ism [2,14].
There is paucity of data about the relation between
the degree of hyperthyroidism, its duration, or its etiol-
ogy and the resulting bone changes. The aim of the pre-
sent study was to evaluate the bone mineral density and
selected bone turnover markers in patients with
hyperthyroidism, also to elucidate the impact of severity,
duration and etiology of hyperthyroidism on these bio-
chemical markers and bone mineral density.
Methods
Subjects
This work included 52 male patients with hyperthyroid-
ism, receiving antithyroid agents during a period of 1-7
years, having normal FT3, FT4 and TSH levels for at
least 6 months prior to the study, among those who
were attending the Endocrine Out Patients Clinic of
Mansoura University Hospitals, 31 with toxic Graves’
disease (GD) and 21 with toxic multinodular goiter
(TNG). Their age ranged from 23 to 65 years. A control
group of 25 healthy men with matched age were
included, their age ranged from 25 to 63 years.
Exclusion criteria included: women to nullify the effect
of gender on the bone status, patients with co-morbidity
(hypo-and hyper parathyroidism, vitamin D deficiency,
Cushing’s disease, diabetic nephropathy, inflammatory
bowel disease, malabsorptive disease or renal diseases)
or on medication (steroid, bisphosphonates, calcium or
vitamin D) influencing bone turnover. Also patients
with history of previous surgery or radiotherapy to the
thyroid gland were excluded.
All participants provided written informed consent
after receiving oral and written information concerning
the study. The study protocol was approved by local
ethical committee of the hospital. All patients and con-
trols were subjected to: Full clinical examination, thyroid
function tests (serum free T3, free T4 and TSH), radio-
active isotope scanning and uptake of the thyroid gland
with Technicium 99.
Methods
In all patients and controls bone mineral density (BMD)
was determined by dual X-ray absorptiometry (DEXA,
Hologic QDR 1000 Analyzer) of the lower half of the
left radius as the non-dominant hand; data were
expressed as a real density in g/m
2 and as Z-score
which is calculated by substracting the mean BMD of
an age, ethnicity and sex matched reference population
from the patients BMD and dividing the difference by
the SD of the reference population.
Special biochemical assays included serum total calcium,
phosphorus, total alkaline phosphatase, bone-specific alka-
line phosphatase (B-ALP), osteocalcin (OC) and carboxy
terminal telopeptide of type l collagen (b-CTx). Also, urin-
ary calcium, urinary deoxypyridinoline (DXP) and urinary
creatinine, were done for both patients and control.
Blood samples were drawn after an overnight fasting
from patients and controls and sera were separated and
divided into 2 plain tubes. Serum obtained from one of
them was used for estimation of total calcium, phos-
phorus and total alkaline phosphatase using Roche
Cobas Integra 400 plus analyzer, Germany[15,16]. The
other tube was centrifuged at 1500 × g for 15 min then
serum was stored frozen at -70°C until analysis of the
following:
- Serum bone specific alkaline phosphatase (B-ALP)
concentration was measured with a non-competitive
enzyme immunoassay technique (Quidel Corporation,
San Diego, CA, USA) [17].
- Serum free T3, free T4 and TSH levels were assayed
by electrochemiluminescence immunoassay using Roche
Elecsys 2010 immunoassay analyzer, Germany [18].
- Serum osteocalcin was analyzed using an immu-
noenzymatic assay for quantitative measurement of
intact human osteocalcin (h-ost) using a kit supplied by
Biosource Europe S.A, Belgium, according to the
method of Power and Fortell (1991) [19].
- Serum carboxy terminal telopeptide of type l col-
lagen (b-CTx) was assayed by electrochemiluminescence
immunoassay using Roche Elecsys 2010 immunoassay
analyzer, Germany [20].
At the same time, urine were collected for twenty four
hours, urine volume measured then 10 ml was stored in
Falcon tubes at -70°C until assay of urine calcium, crea-
tinine and deoxypyridinoline.
El Hadidy et al. BMC Endocrine Disorders 2011, 11:15
http://www.biomedcentral.com/1472-6823/11/15
Page 2 of 7- Urine deoxypyridinoline was analyzed by Immulite
Pyrilinks-D chemiluminscent enzyme-labeled immu-
noassay using Immulite-1000 DPC, Los Angeles, accord-
ing to the method of Reid et al (2004) [21]. Urinary
deoxypyridinoline (DXP) was corrected for urinary crea-
tinine and a ratio of DXP in nmol/l/urinary creatinine
in mg/dl was calculated.
Statistical Methods
Data were statistically analyzed using SPSS computer-
ized package by Fisher’s exact test to compare differ-
ences in rates and Student t-test for differences in
parametric data. Significance of correlation and the rela-
tive contribution of each variable were assessed by
Spearman Rank correlation test. P value < 0.05 was con-
sidered significant.
Results
Table 1: Showed the clinical data (as age, body weight,
hight, body mass index BMI and duration of thyrotoxic
state) and the results for thyroid function test for all
hyperthyroid patients (GD&TNG) and controls.
T a b l e2 :I np a t i e n t sw i t hG Da n dT N G ,t h e r ew e r e
significantly higher serum levels of B-ALP (P < 0.01),
OC (P < 0.0001), b-CTx (P < 0.01) compared to con-
trols. Also urinary calcium/urinary creatinine ratio, urin-
ary DXP and urinary DXP/urinary creatinine ratio were
significantly higher in GD and TNG patients compared
to controls (P < 0.01). At the same time, BMD was sig-
nificantly lower in patients with GD and TNG compared
to controls. However, there were non-significant differ-
ence in patients with Graves’ disease compared to those
with toxic nodular goiter, as regard bone formation
markers (serum B-ALP and osteocalcin), bone resorp-
tion markers (serum b-CTx, urinary calcium/urinary
creatinine, urinary DXP and urinary DXP/urinary creati-
nine ratio) and BMD (P > 0.05).
Correlation between free T3 and biochemical markers
of bone turnover revealed a significant positive
correlation with all studied parameters. B-ALP (r = 0.37,
P < 0.01), serum OC (r = 0.62, P < 0.001), serum b-CTx
(r = 0.60, P < 0.001), urinary calcium/urinary creatinine
ratio (r = 0.46, P < 0.01) and urinary DXP/urinary crea-
tinine ratio (r = 0.52, P < 0.001). Also, correlation
between free T4 and bone turnover markers revealed a
significant positive correlation with B-ALP (r = 0.43, P <
0.01), serum OC (r = 0.65, P < 0.001), serum b-CTx (r
= 0.65, P < 0.001), urinary calcium/urinary creatinine
ratio (r = 0.61, P < 0.001) and urinary DXP/urinary
creatinine ratio (r = 0.49, P < 0.01). While, significant
negative correlation between TSH and biochemical mar-
kers of bone turnover was present, B-ALP (r = -0.39, P
< 0.01), serum OC (r = -0.42, P < 0.01), serum b-CTx (r
= -0.36, P < 0.01), urinary calcium/urinary creatinine (r
= -0.26, P < 0.05) and urinary DXP/urinary creatinine
ratio (r = -0.32, P < 0.05) (Figure 1&2).
Z-score of Bone mineral density measured at the lower
half of the left radius in patients with Graves’ disease
(-1.7 ± 0.5) was not significantly different from those
with toxic multinodular goiter (-1.6 ± 0.6) (table 3).
Correlation between the Z-score of BMD in
hyperthyroid patients and free T3, free T4 as well as
biochemical markers of bone turnover revealed a non-
significant relation with any of them (r value for B-ALP
-0.18, serum OC r = -0.14, Serum b-CTx r = -0.15,
urinary calcium r = -0.09 and urinary DXP/urinary crea-
tinine ratio r = -0.12) (table 4). While, correlation
between duration of the thyrotoxic state and assessed
bone turnover markers revealed a significant positive
correlation with all of them. However, the BMD mea-
sured as real density (g/m
2) or Z-score in the studied
hyperthyroid patients was negatively correlated with the
duration of thyrotoxic state (r = -0.68, P < 0.05) (table
5) (Figure 3).
Discussion
Remodeling is essential for bone health. Remodeling is
coupled with simultaneous formation and resorption of
Table 1 Clinical characteristics and thyroid functions tests of patients with hyperthyroidism (GD and TNG) and
controls.
Parameters GD (n = 31) TNG (n = 21) Controls (n = 25) P1 P2
Age (years) 43 ± 10 44 ± 8 42 ± 11 >0.05 >0.05
Body weight (kg) 69.5 ± 8.0 68.0 ± 12.0 86.0 ± 10.0 <0.05 <0.05
Hight (cm) 170 ± 10 173 ± 10 173 ± 13 >0.05 >0.05
BMI (kg/m
2) 27.5 ± 3.1 27.8 ± 2.8 30.2 ± 2.9 >0.05 >0.05
Duration of disease (years) 2.9 ± 1.2 3.0 ± 1.5 - - -
Serum TSH (uU/ml) 0.89 ± 0.47 1.01 ± 0.36 3.31 ± 0.76 <0.01 <0.01
Serum Free T3 (pmol/l) 6.14 ± 2.32 5.62 ± 1.42 4.57 ± 1.43 <0.01 <0.05
Serum Free T4 (pmol/l) 20.8 ± 6.2 19.8 ± 5.7 17.9 ± 4.26 <0.05 <0.05
P1: Graves’ diseases (GD) vs control
P2: Toxic multinodular goiter (TNG) vs control
Significant P < 0.05
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resorption exceeds formation. This imbalance is aggra-
vated by many disease states [22]. Hyperthyroidism is
one of the conditions associated with bone loss and
increased fracture risk [4,23,24]. Biochemical markers
that reflect remodeling can be assessed in blood or
urine [9,13]. In the present work, we aimed to study
some markers of bone turnover and bone mineral den-
sity and their relation to hyperthyroidism with different
etiology.
The significantly higher bone formation markers
( s e r u mb o n es p e c i f i ca l k a l i n ep h o s p h a t a s ea n ds e r u m
osteocalcin) and bone resorption markers (Serum b-
CTx, urinary calcium and urinary deoxypyridinoline) in
both patients with toxic Graves’ disease and toxic multi-
nodular goiter, found in the present work, confirms the
high turnover state in the skeleton of patients with
hyperthyroidism. There was a significant correlation
between both free T3 and free T4 to B-ALP, serum OC
as bone formations markers, and Serum b-CTx, urinary
calcium/urinary creatinine ratio, urinary DXP and urin-
ary DXP/urinary creatinine ratio as bone resorption
markers. The high bone turnover markers in thyrotoxic
patients with significant decrease in bone mineral den-
sity proved by the Z-score of the studied patients con-
firms the thyrotoxic osteopathy reported by many
authors [2,4,9,14,23-26].
Thyroid hormones affect bone cells both in vitro and
in vivo by stimulating osteoblast and osteoclast cells
with more bone resorption and increased skeletal remo-
deling [27]. The exact mechanism of the deleterious
effect of thyroid hormone on bone is poorly understood
[23,24]. However, some authors reported that, bone loss
in thyrotoxicosis may be as a direct stimulating effect of
excess thyroid hormone acting locally on bone [4]. Also,
TSH deficiency could be partly responsible for the skele-
tal loss seen in thyrotoxicosis [23], because it has been
proposed that TSH may be a direct negative regulator
of bone turnover acting via the TSH receptor on both
osteoblasts and osteoclasts [24,28]. As TSH inhibits
Table 2 Markers of bone turnover and BMD in patients with Graves’ disease and toxic multinodular goiter versus
control.
Parameters GD
(n = 31)
TNG
(n = 21)
Controls
(n = 25)
Significant
P1 P2 P3
Serum B-ALP (KAU/l) 4.9 ± 3.6 4.3 ± 2.6 2.2 ± 0.8 <0.01 <0.01 >0.05
Serum calcium (mg/dl) 9.5 ± 1.0 9.8 ± 1.0 9.8 ± 0.5 >0.05 >0.05 >0.05
Serum phosphorus (mg/dl) 3.9 ± 0.6 4.0 ± 0.6 4.0 ± 0.7 >0.05 >0.05 >0.05
Serum osteocalcin (ng/ml) 12.9 ± 4.0 11.9 ± 4.1 6.6 ± 1.6 <0.0001 <0.0001 >0.05
Serum b-CTx (ug/l) 4.5 ± 0.8 4.1 ± 0.6 3.3 ± 0.6 <0.01 <0.01 >0.05
Ur. calcium/urinary creatinine 0.54 ± 0.07 0.49 ± 0.05 0.36 ± 0.05 <0.001 <0.01 >0.05
UDXP (nmol/l) 68 ± 24 73 ± 22 49.8 ± 26 <0.01 <0.01 >0.05
UDXP/urinary creatinine 12.6 ± 5.5 13.5 ± 5.0 6.3 ± 1.8 <0.001 <0.001 >0.05
BMD at lower radius (g/cm
2) 0.780 ± 0.215 0.799 ± 0.232 0.952 ± 0.170 <0.01 <0.01 >0.05
Data: Mean ± SD
Significant P at < 0.05
  
 
 
 
 
 
 
Figure 1 Positive correlation of Serum FT3 with osteocalcin and b-CTx levels for all hyperthyroid patients.
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Page 4 of 7osteoclast formation and survival and also inhibits
osteoblasts differentiation [29]. In addition, increased
serum interleukin-6 concentration in hyperthyroid
patients favors osteoclasts production may be effectors
of the action of parathyroid hormones on bone [2,4].
Several factors may be incriminated in thyrotoxic bone
loss [30]. Severity and duration of the hyperthyroid state
are related to bone turnover and bone mass [11,31]. In
the present study, duration of the disease was proved to
be significantly related to bone mineral density as mea-
sured by real density and Z-score, also it was
significantly related to the bone turnover markers, both
of bone formation as serum B-ALP and serum OC, or
bone resorption markers as Serum b-CTx, urinary cal-
cium, urinary DXP and urinary DXP/urinary creatinine
ratio. This comes in disagreement with Diamond et al
(1994) who did not find a relation between the duration
of the thyrotoxic state and the degree of bone loss in
their study on pre- and postmenopausal women [32]. It
is noteworthy that the present work studied men while,
they studied pre-and postmenopausal women. Also,
Nekrasova et al (2005) found that, the reduction in
 
 
 
 
 
 
 
Figure 2 Negative Correlation of serum TSH with osteocalcin and b-CTx levels for all hyperthyroid patients.
Table 3 Z-score of bone mineral density in Graves’ disease patients, toxic multinodular goiter patients and controls.
Graves’ Disease
(n = 31)
Toxic Nodular
goiter (n = 21)
Controls
(n = 25)
Significance
P1 P2 P3
Mean ± SD -1.7 ± 0.5 -1.6 ± 0.6 -0.20 ± 0.26 <0.000111 <0.0001 >0.05
P1: Graves’ disease vs controls
P2: Toxic multinodular goiter vs controls.
P3: GD vs TNG
Table 4 Correlation between Z-score of bone mineral density in hyperthyroid patients with thyroid hormones as well
as markers of bone turnover.
Free T3 Free T4 Serum
B-ALP
Serum
OC
Serum
b-CTx
Urinary calcium/
urinary creatinine
Urinary DXP/
urinary creatinine
r = -0.12 r = -0.09 r = -0.18 r = -0.14 r = -0.15 r = -0.09 r = -0.12
P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05 P > 0.05
Table 5 Correlation between duration of thyroid disease with markers of bone turnover and Z-score of BMD at left
radius.
Serum
B-ALP
Serum
Osteocalcin
Serum
b-CTx
Urinary Calcium/
urinary creatnine
UDXP/
urinary creatinine
Z-score
BMD
r value 0.33 0.28 0.29 0.34 0.25 - 0.68
significance <0.01 <0.05 < 0.05 < 0.01 < 0.05 < 0.001
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thyrotoxicosis but this loss of BMD does not depend on
disease duration [31].
Bone densitometric studies proved that all sites of bone
including axial and appendicular skeleton were affected
in patients with hyperthyroidism [33], but Van de ven
and Erdtsieck studies (2008) revealed that changes in cor-
tical bone (appendicular skeleton like femur and radius)
were more prominent than cancellous bone (axial skele-
ton as spine) [4]. In the present study, bone densitometry
was done on the left radius and BMD Z-score for patients
with toxic GD was not significantly different from that of
patients with TNG. Furthermore, markers of bone turn-
over, whether of bone formation (serum B-ALP and OC)
or bone resorption markers (Serum b-CTx, urinary DXP,
urinary DXP/urinary creatinine ratio and urinary cal-
cium/urinary creatinine ratio) were not significantly dif-
ferent in both categories of patients. This finding
confirms the report of Jodar et al (1997) and Belaya et al
(2007), they found no difference in bone mineral density
in patients with Graves’ disease compared to those with
toxic multinodular goiter [7,34].
In the present work, although confirming decreased
bone mineral density in the studied patients, there was a
non-significant relation to either free T3 or free T4 or to
any of the biochemical markers of bone turnover studied
(B-ALP, serum OC, Serum b-CTx, urinary DXP cross-
links, urinary DXP/urinary creatinine ratio and urinary
calcium/urinary creatinine ratio). Variability in the dura-
tion of the thyrotoxic state could be the explanation
behind the discordance between bone mineral density
and severity of thyrotoxic state or bone turnover state.
Conclusion
It is concluded that men with hyperthyroidism have sig-
nificant bone loss with higher biochemical markers of
bone turnover. The severity and duration of hyperthyr-
oidism directly related to the derangement of biochem-
ical markers of bone turnover and to the degree of bone
loss. The etiology of the thyrotoxic state is not related
to the degree of derangement in bone turnover markers
or to the degree of bone loss.
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